Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 130

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 3
Chunk 130
---
 biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
or expiration could adversely affect the combined company financially and could harm its business reputation.

The combined company’s reliance on
third parties requires it to share its trade secrets, which increases the possibility that a competitor will discover them or that its
trade secrets will be misappropriated or disclosed.

Because the combined company
relies on third parties to develop and manufacture its product candidates, the combined company must, at times, share trade secrets with
them. It seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with its collaborators, advisors,
employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights
of the third parties to use or disclose its confidential information, such as trade secrets. Despite the contractual provisions employed
when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by the combined company’s competitors, are inadvertently incorporated into the technology of others, or are
disclosed or used in violation of these agreements. Given that the combined company’s proprietary position is based, in part, on
its know-how and trade secrets, a competitor’s discovery of its trade secrets or other unauthorized use or disclosure would impair
its competitive position and may have a material adverse effect on its business.

Risks Related to the Combined Company’s
Intellectual Property

The combined company has filed multiple
patent applications and have a limited number of issued patents. There can be no assurance that any of its patent applications will result
in issued patents. As a result, the combined company’s ability to protect its proprietary technology in the marketplace may be limited.

The combined company has filed
patent applications in countries worldwide. These applications cover a range of areas including: the U. S., EU, Israel and Japan. While
several patent applications have been granted, several are still pending. Unless and until its pending patent applications are issued,
their protective scope is impossible to determine. It is impossible to predict whether or how many of its patent applications will result
in issued patents. Even if pending applications are issued, they may be issued with coverage significantly narrower than what the combined
company currently seeks. For a description of the combined company’s patent applications and intellectual property, see “ Item
4. Information on the Company - B